PDL BioPharma — Q3 2016 Earnings Presentation
10 slides from PDL BioPharma's earnings presentation, Nov 3, 2016
Slide 1: Third Quarter 2016 Financial Results Conference Call
PDL Third Quarter 2016 Financial Results Conference Call November 3, 2016
Slide 2: Forward Looking Statements
Forward Looking Statements PDL This presentation contains forward-looking statements, including PDI’s expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. A
Slide 3: PDL Evolution in Strategy
PDL Evolution in Strategy O Primary focus remains to increase long term value for our shareholders. QO Have committed over $1.4 billion and deployed ever oad billion since embarking on this strategy in ‘ OQ Shift in strategy provides platform for value creation. = Shift prompted by first equity tran
Slide 4: PDL Noden Background
PDL Noden Background O Noden Pharma = Formed for the purpose of acquiring specialty pharma products. = Domiciled in Ireland but is an operating company with US and EU operations. = Recruiting strong and seasoned management team: o CEO of Noden, Elie Farah: Was CEO for Merus Labs in acquisition and s
Slide 5: Tekturna, Noden's Flagship Product
PDL Tekturna, Noden’s Flagship Product QO Tekturna, for the treatment of hypertension * Tekturna and Tekturna HCT (known as Rasilez® in EU) consist of the direct renin inhibitor, aliskiren, as a monotherapy and as a fixed-dose combination with the diuretic hiyarodilenethiazide, respectively. = Tektu
Slide 6: Royalty Acquisition
Rovalty Acquisition ky bella ‘$9,500,000 “uly 2016 Royalty Acquisition 16 Royalty & Debt Investments Senior Secured Rovalty Acquisition AicelRx $65,000,000 September2015 Royalty Acquisition RIAD pt0 $10,000,000 ‘uly 2015, Royalty Acquisition ‘tune 2015, Senior Secured Note $15,500,000 “une 2018 Roya
Slide 7: PDL Strategy
PDL PDL Strategy ¥ Acquiring additional specialty pharma products for Noden Pharma DAC. Specialty Pharma Y Significant focus. v Using proceeds from completed deals to fund new product acquisiti Royalty & Debt Deals Fewer royalty still fewer debt transactio Data from Eli Lilly’s Phase 3 trial in pati
Slide 8: Third Quarter Ended September 30, 2016 Overview
Third Quarter Ended PDL September 30, 2016 Overview ‘Three Months Ended Nine Months Ended Sentertber 30. Senterrber 30. in thousends, except per share smounts) 2016 2015 216 15. oyalies from Queen el patents S$ 14958 _$ 119202 _$ 150,645 _$ 362,916 oyaly rights - change in fair value 16,085 (4280 (1
Slide 9: PDL Investment Highlights
PDL Investment Highlights Q Tekturna and Tekturna HCT are important unique products for treatment of hypertension with potential upside in revenues if promoted appropriately. QO Noden is a tax efficient vehicle and additional spec pharma products will be added. QO 16 royalty and debt deals with 11 o
Slide 10: Question and Answer Session
PDL Question and Answer Session